Table 2.
Summary HBV genotype responses to CHB treatment by IFNα or PEG-IFNα and NUCs.
| Genotype | Response to Treatment | Reference | |
|---|---|---|---|
| IFNα or PEG-IFNα | NUCs | ||
| A | weak responder to IFNα; strong responder to PEG-IFNα |
strong responder to NUCs; drug resistance noted |
[21,22] |
| B | strong responder to IFNα; strong responder to PEG-IFNα |
strong responder to NUCs; drug resistance noted |
[21,22,23] |
| C | weak responder to IFNα; weak responder to PEG-IFNα |
weak responder to NUCs | [21,23] |
| D | weak responder to IFNα; weak responder to PEG-IFNα |
weak responder to NUCs | [21] |
| E | strong responder to IFNα; weak responder to PEG-IFNα |
adequate responder to NUCs | [24,25] |
| F | weak responder to IFNα | adequate responder to NUCs | [24] |
| G | stronger response to IFNα | adequate responder to NUCs | [24] |
| H | weaker response to IFNα | adequate responder to NUCs | [24] |
| I | [25] | ||
| J | [25] | ||